Background
==========

Human cytomegalovirus (CMV) is the viral agent most frequently associated with congenital infections in man. Although 90% of CMV congenitally infected infants are asymptomatic at birth, approximately 10% develop cytomegalic inclusion diseases, with a 20--30% mortality rate \[[@B1]\]. However, up to age 2, 10--15% of asymptomatic children develop neurological sequelae \[[@B2]\], such as sensorineural hearing loss, mental retardation, motor deficits, seizures and chorioretinitis. CMV has been observed in infants born to mothers who were seropositive before pregnancy \[[@B3],[@B4]\]. Postnatal disease, though generally asymptomatic, frequently occurs in infants with hepatic involvement.

Several epidemiological studies on the incidence of the virus and the long-term sequelae of congenital CMV infection have been carried out in the United States, UK and Italy \[[@B5]-[@B7]\].

A vaccine against CMV is currently under development \[[@B8],[@B9]\], and new antiviral therapy for symptomatic new-borns is under study \[[@B10]\].

Detection of CMV DNA by PCR amplification contributes to a rapid and early diagnosis \[[@B11]\]. A large variety of primers have been used for the detection of CMV DNA by PCR, but the problem to select suitable primers has prompted studies in several laboratories, because the variations in the viral genome sequence found in strains circulating in diverse populations have been shown to affect the ability of the reaction to detect CMV DNA \[[@B1],[@B12],[@B13]\].

We analysed the efficacy of three sets of primers that amplify three different regions of CMV genomes for the early diagnosis of CMV infections in a selected group of 61 newborns with congenital or perinatal infection. The best conditions in terms of primers, to confirm the clinical suspicion of congenital or postnatal CMV infection, can be established by tests on CMV isolates or by direct work on urine samples. We performed the test on CMV isolates with 80% of cytopathic effect to standardise the method and ensure enough viral DNA so that PCR amplification would not be conditioned by this factor. The results herein presented allowed the selection of suitable gB primers for PCR of urine and DBS samples and their correlation with serology data.

Methods
=======

Population
----------

Sixty-one patients with positive virological results were selected from a group of 237 newborns with signs and symptoms compatible with HCMV diseases. Only 3 out of 33 congenital infection patients had low body weight as sole symptom (Table [1](#T1){ref-type="table"}). The series consisted of urine and serum samples from 61 patients. Samples for congenital infection diagnosis were collected at 1--21 days, and for perinatal infection at 4.5 ± 3.5 months. Both samples were collected simultaneously. CMV infection was confirmed by urine cultures performed during routine activities at our laboratory. Dried blood spots (DBS) were collected from 11 babies, 3 during the early days of life, and from the remaining 8, who were studied retrospectively, at 24 days, 40 days, 34 days, 3 months, 2 at 5 months, 8 months and 20 months.

###### 

Clinical findings in 61 infants with congenital and perinatal infection and specific IgM antibodies to Cytomegalovirus detected by enzymoimmunoassay

  **Congenital**                                             
  ----------------------------- ---------------- ----------- -----------------------------------------------------------------------------------------------
  1                             5 d              \+          IUGR, cerebral calcifications.
  2                             21 d             \-          Ascites, renal problems, elevated liver enzymes.
  3                             6 d              \+          SGA, purpura, hepatosplenomegaly
  4, 8, 29                      5 d, 5 d, 28 d   -, +, +     SGA
  5                             18 d             \+          Petechiae, hepatosplenomegaly, jaundice
  6, 14., 32                    5 d, 8 d, 8 d    +, +, +     Hepatosplenomegaly, cerebral calcifications
  7                             14 d             \+          Sepsis, thrombocytopenia.
  9                             20 m             \-          AWGA, purpura, elevated liver enzymes.
  10                            5 d              \+          SGA, cerebral microcalcifications, microcephaly
  11                            5 d              \-          SGA, purpura, hepatosplenomegaly, thrombocytopenia
  12                            4 d              \-          AWGA, purpura, elevated liver enzymes, trombocytopenia.
  13                            11 d             \+          Sepsis, petechiae, thrombocytopenia
  15, 21, 33                    5 d, 5 d, 5 d    -, +, -     SGA, purpura, HIV+.
  16                            6 d              \-          Cerebral calcifications, thrombocytopenia, HIV+ mother.
  17                            5 d              \+          Foetal dystrophy, inclusion-bearing cells in urine.
  18                            14 d             S/s         IUGR, sepsis, foetal dystrophy
  19                            8 d              \+          Hepatosplenomegaly, sepsis, died of hepatic failure
  20                            18 d             \+          SGA, hydrocephalus, respiratory problems
  22                            3 m              S/s         Cerebral calcifications, congenital toxoplasmosis
  23                            24 d             \-          Cholestasis, purpura, cerebral calcifications, elevated liver enzymes, sepsis.
  24                            5 d              \-          Microcephaly, cerebral calcifications (irregular and punctate), thrombocytopenia
  25                            5 d              \+          AWGA, hepatosplenomegaly, sepsis, jaundice.
  26                            3 m              \-          Chorioretinitis
  27                            5 d              \-          SGA, hepatosplenomegaly, petechiae, anaemia, cholestasis
  28                            5 d              \+          SGA, purpura, cerebral calcifications, thrombocytopenia, splenomegaly, elevated liver enzymes
  30                            5 d              \+          Hepatosplenomegaly, purpura
  31                            5 m              \-          RNPT, AWGA, seizures, maturational delay, palsy at age one year
  **Perinatal**                                              
  39                            40 d             \-          SGA, petechiae, hepatomegaly, respiratory problems.
  41                            5 m              \+          HIV+, cerebral calcifications, hepatosplenomegaly, anaemia
  47                            34 d             \+          Neonatal jaundice
  50                            8 m              \-          SGA, Hepatosplenomegaly, elevated liver enzymes, anaemia, jaundice at age 2 months
  **Congenital or Perinatal**                                
  34, 37, 48                    3 m, 8 m, 7 m    -, -, S/s   Hepatosplenomegaly, HIV+
  35                            4 m              \+          Jaundice, biliary atresia
  36                            63 d             \+          Anaemia, hepatosplenomegaly, malnutrition, hyperbilirubinemia
  38, 43                        4 m, 3 m         -, -        Petechiae, hyperbilirubinemia, splenomegaly
  40                            40 d             \-          Ascitis, renal problems, elevated liver enzymes
  42                            42 d             S/s         SGA
  44                            3 m              \+          Premature, scanty maternal contact
  45                            24 m             \-          Malnutrition, pancytopenia.
  46                            12 m             \+          Aplastic crisis
  49                            4 m              \+          SGA, hepatosplenomegaly, jaundice, anaemia, petechiae.
  51                            2 m              \+          Sepsis, cyanosis, vomiting
  52                            1 m              S/s         Petechiae, jaundice, anaemia, hepatosplenomegaly
  53                            5 m              \+          Mental retardation, anaemia
  54                            2 m              \-          RNPT, SGA, IUGR, anaemia, microcephaly, tricuspid valve insufficiency
  55                            3 m              \-          SGA, rash, fever spikes
  56, 58                        5 m, 33 d        -, -        SGA, respiratory problems.
  57                            34 d             \+          IUGR, sepsis, hepatomegaly, oesophageal atresia, elevated liver enzymes
  59                            26 d             \-          SGA, HIV+ mother
  60                            38 d             \+          IUGR, microcephaly, jaundice
  61                            6 m              \-          Normal at birth, neutropenia

IUGR, intrauterine growth retardation; SGA, small for gestational age; AWGA, adequate weight for gestational age. S/s, sera not collected

Congenital infection was diagnosed in 33 cases, while the 28 remaining cases were grouped as perinatal infections, althugh they should be conceptually grouped as \"congenital or perinatal\" infections, since in only 4 cases could the perinatal origin of the infection be demonstrated by analysing two samples, one taken at the time of birth and the other when the disease was clinically manifest.

Virological Methods: Urine samples were processed in parallel by PCR and culture, DBS by PCR and serum was tested by solid-phase enzymatic immunoassay (Organon Teknika).

Processing of clinical samples
------------------------------

### Isolation of CMV in cell cultures and confirmation by an indirect immunofluorescence test

Two to 10 ml of urine were collected in sterile bags. A portion was tested by culture and the rest was stored at -20°C for direct PCR (with no previous DNA extraction).

For isolation of CMV, urine samples were pre-filtered through 0.2-μm membranes, and inoculated (200 μl) in PTP monolayers, a human foreskin fibroblast cell line established by the Service of Tissue Culture (INEI, ANLIS Dr. Carlos G. Malbrán). Eagle\'s minimum essential medium (Gibco) containing 2% foetal calf serum (Gibco) was used to maintain the cell line. A 200-μl aliquot was inoculated on a confluent monolayer of fibroblasts, and then incubated at 37°C for up to 3 weeks. Eagle\'s was replaced every 7 days, and fibroblasts were examined every 48 h until appearance of typical viral cytopathic effect. Positive cultures were suspended, washed with phosphate buffer (PBS) and fixed with acetone. For direct immunofluorescence, cells were incubated at 37°C for 45 min using a monoclonal antibody to CMV late antigen (Whittaker, Bioprod and Chemicon Intl.), and washed. Later, they were incubated at 37°C for 30 min in FITC-labelled, anti-mouse rabbit serum (Dako), washed again, and then observed by fluorescence microscopy.

### Serology

The presence of CMV-IgM antibody was determined by an enzyme-linked immunoabsorbent assay (Vironostika anti-CMV IgM II, Organon Teknika), according to the manufacturer\'s instructions.

CMV-PCR
-------

### Sample preparation

#### Tissue culture

CMV isolates with 80% of cytopathic effect in PTP cells were treated with Trypsin--Versene, washed and suspended in maintenance medium (MM). For DNA release, 1 ml of this suspension was heated at 55°C for 60 min and then at 100°C for 7 min, and further centrifuged at 10,000 rpm for 3 min. The supernatant was transferred to another Eppendorf tube and frozen at -80°C for at least 1 hour. Thus, it could be used as a template for PCR.

#### Urine

5 μl of each urine sample were directly amplified by n-PCR (with no previous DNA release), with the primers directed to the gB region. Negative samples were diluted with sterile deionized water (50%), in order to dilute inhibitors \[[@B1]\].

#### Blood Spots

The extraction of CMVDNA in DBS on Guthrie Cards obtained from 11 neonates was performed following the method of Shibata et al. \[[@B14]\] with the modifications introduced by M. Barbi et al. \[[@B15]\].

### Reaction

The PCR method for the detection of CMV was carried out with previously described oligonucleotide primers for the major immediate-early (MIE) fragment region (IV exon de IE1, 242 pb \[[@B1],[@B15]\], glycoprotein B (gB) gene (ORF UL55), 150 pb \[[@B11],[@B16],[@B17]\], and late antigen (LA) (ppUL83), 400 pb \[[@B1]\].

Table [2](#T2){ref-type="table"} shows the sequences of the oligonucleotide primers herein used. Reaction mixtures consisted of 5 μl of target DNA, 10 pmol of each oligonucleotide primer, for LA primers 2.5 U/μl of enzyme Taq polymerase (Perkin-Elmer Cetus, Nowalk) and 2.0 U/μl for gB and IE primers, 200 μM (each) of deoxynucleotide triphosphate, 5 μl of 10X reaction buffer (500 mM KCl, 10 mM tris-HCl, pH 8.3, 1.5 mM MgCl~2~, 0.01% gelatin), and high-pressure liquid chromatography distilled water to a total volume of 50 μl in an Eppendorf tube. A negative control reaction tube received only 50 μl of reaction mixture. A positive control was carried out with the pattern strain kindly provided by Dr. María Barbi from the Istituto di Virologia, Università degli Studi di Milano. Different cycles of amplification were carried out using a DNA thermocycler (GeneAmp 2400, Perking-Elmer Cetus). Amplification conditions were those described by the authors, with only minor changes: region LA, 40 cycles of denaturation at 94°C for 105 sec, annealing at 65°C for 75 sec and extension at 72°C for 60 sec; each extension period was increased by 10 sec on each subsequent cycle; region gB, 35 cycles of denaturation at 94°C for 15 sec, annealing at 58°C for 15 sec and extension 72°C for 15 sec; the second amplification differed from the first in that 30 cycles were performed and the annealing temperature was 50°C; region IE, 35 cycles of denaturation at 94°C for 15 sec annealing at 55°C. for 15 sec and extension 72°C for 15 sec. One initial denaturation at 94°C, 2 min and one final extension at 72°C, 5 min were carried out in all amplifications.

###### 

Sequences of oligonucleotide primers used for the amplification of HCMV genome

  **Primers**   **Sequence**(5-3)\'         **Product Length (pb)**   **Position in the gene**   **References**
  ------------- --------------------------- ------------------------- -------------------------- --------------------------
  IE            tgaggataagcgggagatgt        242                       1729--1748                 Jiwa N et al. (1989)
                actgaggcaagttctgcagt                                  1951--1970                 
  gB            Outer                                                                            
                accaccgcactgaggaatgtcag     150                       1942--1966                 Darlington et al. (1985)
                tcaatcatgcgtttgaagaggta                               2067--2091                 
                inner                                                                            
                accaccgcactgaggaatgtcag     100                       1967--1989                 
                tcaatcatgcgtttgaagaggta                               2066--2040                 
  LA            cacctgtcaccgctgctatatttgc   400                       1967--1989                 Demmler G et al. (1998)
                caccacgcagcggcccttgatgttt                             2066--2040                 

Aliquots (18 μl) of each PCR-amplified product were electrophoresed on 2% agarose gel (Sigma A-7431) containing 0.5 μg/ml of ethidium bromide and were visualised and photographed with UV light (Fig. [1](#F1){ref-type="fig"}).

![Ethidium bromide--stained agarose gel electrophoresis: analysis of DNA amplified with primers MIE, gB, LA. Samples (M) the different newborns (M1, M2, M3, M4). MP 100 bp DNA marker](1471-2431-4-11-1){#F1}

### Specificity of PCR reaction

These primers have previously failed to amplify other herpes viruses and cellular DNA.

### PCR positivity rates of reaction

To estimate the PCR positivity rates, with the primers gB, IE and LA relative to tissue culture, cells infected with the pattern strain (Towne) were allowed to develop up to 80% cytopathic effect, and released DNA (as described in sample preparation) was analysed by undiluted PCR and with 1/50, 1/100,1/200, 1/300 and 1/400 dilutions.

Results
=======

PCR positivity rates
--------------------

Primers gB were amplified up to 1/300 dilution, primers IE up to 1/100 and LA up to 1/50.

### PCR from CMV isolates

PCR from CMV positive cultures with gB primers were positive in oll cases, unlike primers directed to the other regions (Fig. [1](#F1){ref-type="fig"}); gB primer amplified 61/61 samples; IE 33/61 (12 congenital and 21 out of those grouped and LA 37/61 (19 congenital and 18 out of those grouped. Thus, the PCR positivity rates of primers was 100% for gB, 54% for IE, and 61% for LA.

### PCR of urine samples using primers for the gB region

Definite PCR results using primers that amplify the gB region in positive cell cultures was higher (61/61) than those obtained by direct PCR (with no previous DNA release) in urine samples from the same patients: 34/61 (56%), although 24 out of 33 patients with congenital infection (73%) were positive (Table [3](#T3){ref-type="table"}). When nPCR was used in the same samples, 100% of patients with congenital infection and 26 (93%) with samples grouped as perinatal infection were positive (Table [2](#T2){ref-type="table"}).

###### 

Detection of HCMV by PCR/nPCR with gB primers in CMV isolates and urine

  **[Samples]{.ul}**     **[Methods]{.ul}**               **infection**    **Positive (%)**   **Total positive (%)**
  ---------------------- -------------------------------- ---------------- ------------------ ------------------------
  **Positive culture**   PCR                              Congenital       33 (100)           61 (100)
                                                          Perinatal \*\*   28 (100)           
  **[Urine]{.ul}**       Direct PCR without DNA release   Congenital       24 (73)            34 (56)
                                                          Perinatal\*\*    10 (36)            
  **[Urine]{.ul}**       n-PCR                            Congenital       33 (100)           59 (97)
                                                          Perinatal\*\*    26 (93)\*          

\* from the 3 negative samples, one of which became positive when a dilution was made \*\* samples grouped as perinatal

### PCR of (DBS) using primers for the gB region

Out of the 11 patients studied, 3 were newborn (pts. 6, 10 and 24), and out of the remaining 8, four aged, 20 months, 3 months, 24 days, and 5 months (pts. 9, 22, 23, and 31) were positive, while the other four aged 40 days, 5 months, 34 days and 8 months (pts. 39, 41, 47 and 50) were negative.

Discussion
==========

Out of a group of 237 children of CMV infection, 61 samples were selected with positive isolation, 33 of which presented congenital infection, while the remaining 28 were grouped as perinatal infection; although in only 4 could perinatal infection be demonstrated and the other 24 could be either perinatal or congenital. The frequency of positive cases in laboratory tests carried out was 14% (33/237). of children with congenital infection, 4.66% annual. This is a high frequency because the patients came from a population of low economic resources with a high seroprevalence of IgG for CMV, a result only explained by the fact that all cases reaching our laboratory come from suspected patients \[[@B18]\].

Amplification by PCR is frequently used in diagnostic laboratories for the detection of CMV. As the choice of PCR primers for CMV is crucial, three primer pairs were selected from the literature, the IE and LA \[[@B1]-[@B12]\], which amplify fragments of the early and late regions of the genome respectively; and the gB \[[@B11],[@B16],[@B17]\], which amplifies a fragment of the region that encodes the glycoprotein B. These primers were designed from the pattern strains AD169 and Towne, and they amplify genome regions that are considered conserved, due to their functional properties. In order to unify the conditions of amplification, CMV DNA extracted from cultures with an 80% of viral cytopathic effect was used in all cases.

Several authors have found that the exon 4 region of the IE gene was highly variable, and that nucleotide substitution was distributed along the gene \[[@B19],[@B20]\]. These variations would result in alterations in the aa sequence of 12 positions (13%). The biological meaning of these variations is yet unknown.

Fewer studies have been conducted on LA primers. In 1988, Shibata et al. \[[@B21]\] amplified 28 samples of viral isolates positive for CMV by PCR using IE and LA primers. They found that one sample was amplified by the IE primers but not by the LA, whereas the other sample was amplified by the LA primer but not by the IE.

In this study, the efficacy of LA primers in amplifying samples from newborns was higher than that of IE primers (61% and 54%, respectively). Although these primers are the most frequently used for laboratory diagnosis, the results herein obtained indicate that their use is not advisable for the newborn population.

Differences in the PCR positivity rates of detection of the viral genome among samples of patients studied by diverse authors and those included in our study were probably due to the design of the primers. Even though sensitivity with the diverse primers is variable (gB 1/300, IE 1/100, LA 1/50), this factor would be negligible when using an excess of virus unless the DNA release method were efficient enough. Another factor to be considered is that the number of passages in cell culture of viral isolates analysed by PCR is too low to cause variations that could affect the PCR reaction in conserved DNA sequences. Sequencing of the IE and LA region of those strains that failed to be amplified by the primers would confirm this hypothesis.

In samples from studied patients, the PCR positivy rates for gB with CMV isolates was 100% compared with the gold-standard (tissue culture). Since gB primers were the most suitable for the study of congenital infection in Argentina, we attempted to determine whether these primers were also effective when direct amplification (with no previous DNA release) of urine samples was performed in our patients. Viral genome was found in all samples by nPCR (Table [3](#T3){ref-type="table"}) but positive results were found by PCR in 56% (34 patients) of the cases, including two asymptomatic patients. On the other hand, in 33 congenital infection patients, positive results were observed in 73% (24 patients), so that we may infer that in most cases of congenital infection in symptomatic patients, CMV infection may be detected by a single amplification in urine. In these patients grouped as perinatal infection there were three negative samples: one became positive after dilution, and the other two were negative. This could be associated with low viral elimination, sample alteration during shipping or presence of inhibitory factors in urine, since no purification was used. Samples from 11 patients were studied by DBS PCR at the time of birth, 8 of which were evaluated retrospectively, thus allowing the congenital source of infection to be determined in four cases. Likewise, 4 cases of perinatal infection were confirmed by this same technique.

Serology is a technique widely used in most laboratories, despite its low sensitivity \[[@B18]-[@B22]\], so that it has also been included in this study in order to discern the sensitivity of the serological method used in our laboratory. However, there were no significant differences between the serology in patients with congenital infection and those grouped as perinatal. Therefore, an accurate diagnostic method such as PCR is highly advisable for the management of congenital infection in new-borns during the first three weeks of life. Viral isolation is very limited in our country due the expense of specialised labour and the need of a special tissue culture laboratory, so that PCR provides a valid alternative.

Finally, given the large size of the CMV genome, and despite the homogeneity among clinical isolates, sequence studies should comprise more strains. More importantly, there must be consensus on the type of primers to be used, since it has been demonstrated that slight and sometimes silent variations in the sequence may alter PCR sensitivity, thus leading to misdiagnoses.
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